3-氟-4-甲基吡啶-2-甲腈 | 312904-99-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-氟-4-甲基吡啶-2-甲腈
• 英文名称: 2-cyano-3-fluoro-4-methylpyridine
• 英文别名: 3-fluoro-4-methylpicolinonitrile；3-fluoro-4-methylpyridine-2-carbonitrile
• CAS: 312904-99-7
• 化学式: C₇H₅FN₂
• 分子量: 136.129
• InChiKey: KMNYPJRYCDTVLC-UHFFFAOYSA-N

物化性质

• 沸点：
  242℃
• 密度：
  1.19
• 闪点：
  100℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-氟-4-甲基吡啶-2-甲腈 在 palladium on activated charcoal N-甲基吗啉 、 盐酸 、 氢气 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 40.0h， 生成 2-[3-(2,2-Difluoro-2-phenyl-ethylamino)-6-methyl-2-oxo-2H-pyrazin-1-yl]-N-(3-fluoro-4-methyl-pyridin-2-ylmethyl)-acetamide
  参考文献：
  名称：

  Metabolism-Directed Optimization of 3-Aminopyrazinone Acetamide Thrombin Inhibitors. Development of an Orally Bioavailable Series Containing P1 and P3 Pyridines

  摘要：

  Recent efforts in the field of thrombin inhibitor research have focused on the identification of compounds with good oral bioavailability and pharmacokinetics. In this manuscript we describe a metabolism-based approach to the optimization of the 3-(2-phenethylamino)-6-methylpyrazinone acetamide template (e.g., 1) which resulted in the,modification of each of the three principal components (i.e., P1, P2, P3) comprising this series. As a result of these studies, several potent thrombin inhibitors (e.g., 20, 24, 25) were identified which exhibit high levels of oral bioavailability and long plasma half-lives.

  DOI：

  10.1021/jm020311f
• 作为产物：
  描述：

  3-氟吡啶 在 碳酸氢钠 、 三乙胺 、 间氯过氧苯甲酸 、 lithium diisopropyl amide 作用下， 以 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 54.0h， 生成 3-氟-4-甲基吡啶-2-甲腈
  参考文献：
  名称：

  Metabolism-Directed Optimization of 3-Aminopyrazinone Acetamide Thrombin Inhibitors. Development of an Orally Bioavailable Series Containing P1 and P3 Pyridines

  摘要：

  Recent efforts in the field of thrombin inhibitor research have focused on the identification of compounds with good oral bioavailability and pharmacokinetics. In this manuscript we describe a metabolism-based approach to the optimization of the 3-(2-phenethylamino)-6-methylpyrazinone acetamide template (e.g., 1) which resulted in the,modification of each of the three principal components (i.e., P1, P2, P3) comprising this series. As a result of these studies, several potent thrombin inhibitors (e.g., 20, 24, 25) were identified which exhibit high levels of oral bioavailability and long plasma half-lives.

  DOI：

  10.1021/jm020311f

文献信息

• Thrombin inhibitors
  申请人：Merck & Co., Inc.

  公开号：US06350745B1

  公开（公告）日：2002-02-26

  Compounds of the invention, useful as thrombin inhibitors and having therapeutic value in for example, preventing coronary artery disease, have the following structure: or a pharmaceutically acceptable salt thereof, wherein A is wherein Y1 and Y2 are independently hydrogen, C1-4 alkyl, C1-4 alkoxy, FuHvC(CH2)0-1 O—, wherein u and v are either 1 or 2, provided that when u is 1, v is 2, and when u is 2, v is 1, C3-7 cycloalkyl, thio C1-4 alkyl, C1-4 sulfinylalkyl, C1-4 sulfonylalkyl, halogen cyano, or trifluoromethyl, and wherein b is 0 or 1.

  该发明的化合物可用作凝血酶抑制剂，在预防冠状动脉疾病等方面具有治疗价值，具有以下结构： 或其药学上可接受的盐，其中 A为 其中 Y1和Y2独立地为 氢， C1-4烷基， C1-4烷氧基， FuHvC(CH2)0-1 O—，其中u和v均为1或2，但当u为1时，v为2，当u为2时，v为1， C3-7环烷基， 硫代C1-4烷基， C1-4亚砜基烷基， C1-4磺酰基烷基， 卤素 氰基，或 三氟甲基，并且 其中b为0或1。
• [EN] THERAPEUTIC INHIBITORY COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS THÉRAPEUTIQUES
  申请人：LIFESCI PHARMACEUTICALS INC

  公开号：WO2015103317A1

  公开（公告）日：2015-07-09

  The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

  该发明提供了Formula I和Formula II的化合物：A-B-C-D-E-F-G-J (I)和C-D-E-F-G-J (II)，其中A、B、C、D、E、F、G和J具有规范中定义的任何值，以及它们的盐。这些化合物对抑制血浆激肽酶和治疗动物中需要抑制血浆激肽酶的疾病或症状是有用的。
• Pyrazinone thrombin inhibitors
  申请人：Merck & Co., Inc.

  公开号：US06455532B1

  公开（公告）日：2002-09-24

  Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: A is  wherein Y1 and Y2 are independently hydrogen, C1-4 alkyl, C1-4 alkoxy, FuHvC(CH2)0-1 O—, wherein u and v are either 1 or 2, provided that when u is 1, v is 2, and when u is 2, v is 1, C3-7 cycloalkyl, thio C1-4 alkyl, C1-4 sulfinylalkyl, C1-4 sulfonylalkyl, halogen cyano, or trifluoromethyl, and wherein b is 0 or 1.

  该发明的化合物在抑制凝血酶和相关血栓闭塞方面具有用处，具有以下结构：A是其中Y1和Y2独立地是氢、C1-4烷基、C1-4烷氧基、FuHvC(CH2)0-1O—，其中u和v均为1或2，但当u为1时，v为2，当u为2时，v为1，C3-7环烷基、硫代C1-4烷基、C1-4亚砜基烷基、C1-4砜基烷基、卤代氰基或三氟甲基，其中b为0或1。
• Non-nucleoside reverse transcriptase inhibitors
  申请人：Anthony Neville J.

  公开号：US20080275097A1

  公开（公告）日：2008-11-06

  Compounds of Formula I: are HIV reverse transcriptase inhibitors, wherein V, W, X, Y, Z, R 1 , R 2 , R 4 , R 5 , R 6 , ring A, ring B, j and k are defined herein. The compounds of Formula I, and the pharmaceutically acceptable salts and prodrugs thereof, are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  化合物I的公式是HIV反转录酶抑制剂，其中V、W、X、Y、Z、R1、R2、R4、R5、R6、环A、环B、j和k在此定义。化合物I及其医药上可接受的盐和前药在抑制HIV反转录酶、预防和治疗HIV感染以及预防、延迟发病或进展和治疗艾滋病方面具有用途。这些化合物及其盐可以与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用作为药物组成部分。
• NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
  申请人：Tucker Thomas J.

  公开号：US20100256181A1

  公开（公告）日：2010-10-07

  Heteroaromatic compounds of Formula (I) are HIV reverse transcriptase inhibitors, wherein ring A is: (ii-a), (ii-b), (ii-c), (ii-d), or (ii-e); and wherein n, L, M, U, X, Y, Z, R E , R F , R 1 , R 2A , R 2B , R 2C , R 3 , R 8 , R 9 and R 10 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts and prodrugs are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts and prodrugs can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  公式（I）的杂环芳香化合物是HIV反转录酶抑制剂，其中环A为：（ii-a）、（ii-b）、（ii-c）、（ii-d）或（ii-e）；其中n、L、M、U、X、Y、Z、RE、RF、R1、R2A、R2B、R2C、R3、R8、R9和R10的定义见本文。公式I的化合物及其药学上可接受的盐和前药在抑制HIV反转录酶、预防和治疗HIV感染以及预防、延迟发病或进展和治疗艾滋病方面有用。这些化合物及其盐和前药可作为药物组成部分，可与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。